Processa Pharmaceuticals plans to expand the development of Next Generation Capecitabine into the treatment of advanced or metastatic breast cancer beginning with its next Phase 2 trial. Following the Processa meeting with the FDA, Processa has decided the next NGC-Cap trial would be a Phase 2 trial in breast cancer. This decision was supported through discussions with the FDA where Processa agreed with the FDA that pursuing breast cancer will lead to a more efficient development program while providing a greater likelihood of FDA approval. The FDA stated that the previously generated data in past and existing studies could be used to directly support the Phase 2 trial in breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCSA:
- Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
- Processa Pharmaceuticals to effect 1-for-20 reverse stock split
- Processa Pharmaceuticals to Present at the Biotech Showcase 2024
- Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
- Processa provides interim analysis from Phase 1b trial of NGC-Cap